Clinical Characteristics and Prognosis of Young Patients with Coronary Heart Disease

BCF 1 Ruyi Zheng
BDE 1 Yan Liu
F 2 Zirui Hao
BF 1 Huocheng Liao
BCF 1 Chun Xiao

Corresponding Author: Chun Xiao, e-mail: Huizhouxiaoc@163.com
Source of support: Departmental sources

Background: The objective of this study was to investigate the clinical characteristics and prognosis of coronary heart disease (CHD) in young patients.

Material/Methods: We included 972 CHD patients (≤50 years old) with coronary artery stenting who were prospectively enrolled and followed for 1 year. Clinical characteristics, risk factors, and predictors of outcomes were evaluated.

Results: The prevalence of current smoker, hypertension, diabetes mellitus, dyslipidemia and positive family history of CHD were 18.9%, 34.3%, 14.5%, 4.4%, and 44.2%, respectively. Most of the patients underwent coronary stenting due to stable angina (48.8%) and unstable angina (UA; 48.1%). After 1-year follow-up, 64 patients (6.6%) experienced clinical outcomes and the most common event was UA (n=56). Compared to patients without clinical outcomes, those with outcomes were more likely to be male, have higher systolic blood pressure, more likely to have hypertension and diabetes mellitus, and more likely to be presented as unstable angina. Multivariate regression analysis showed only age (hazard ratio [HR]: 1.12 and 95% confidence interval [CI]: 1.07–1.26), smoking (HR: 1.15 and 95% CI: 1.06–1.23), presence of hypertension (HR: 1.19 and 95% CI: 1.13–1.31), and diabetes mellitus (HR: 1.27 and 95% CI: 1.20–1.48) and presented with acute coronary syndrome (HR: 1.35 and 95% CI: 1.21–1.55) were independently associated with clinical outcomes.

Conclusions: Most of the young (≤50 years of age) CHD patients had poor management of risk factors and better controlling these risk factors would be helpful for the primary and secondary prevention of premature CHD in Guangdong province.

MeSH Keywords: Coronary Disease • Outcome Assessment (Health Care) • Risk Factors

Full-text PDF: https://www.medscimonit.com/abstract/index/idArt/922957
Background

Coronary heart disease (CHD) is a leading cause of morbidity and mortality in developed and developing countries [1–4]. Hypertension, dyslipidemia, diabetes mellitus and smoking are major risk factors for CHD. Prior randomized clinical trials and prospective cohort studies have consistently demonstrated that controlling these risk factors is beneficial for primary and secondary prevention of CHD in the overall populations [5–7].

A recent report of the China Patient-centered Evaluation Assessment of Cardiac Events (China PEACE) study found that the incidence of ST-segment elevation myocardial infarction (STEMI) in China from 2001 to 2011 was gradually increased [8]. A report from the Chinese Ministry of Health epidemiological survey additionally showed that the prevalence and incidence of CHD among Chinese young populations has also increased [9], which was postulated to be attributed to the pandemic of cigarette smoking, hypertension, diabetes mellitus, and dyslipidemia. These data together support the notion that controlling risk factors would be beneficial to reduce health and economic burdens of CHD in China [10].

A recent retrospective study showed that the overall incidence of cardiac death and major adverse cardiovascular event of the young Chinese CHD patients had increased compared to the past decades [11]. However, this study was compromised by its retrospective design. The aim of current study was to evaluate the clinical characteristics, risk factors associated with CHD severity, and predictors of cardiovascular outcomes in young CHD patients after coronary artery stenting. From a clinical standpoint, this information will not only help better understand the clinical features of premature CHD, but also will provide information about potential therapeutic targets that physicians should focus on in the future.

Material and Methods

Study participants enrollment

This study was approved by the Ethics Committee of Clinical Research of The Third People’s Hospital of Huizhou and informed consent was obtained before participants’ enrollment. Inclusion criteria were as follows: ≤50 years old and had angiographical-diagnosis of CHD and had underwent coronary artery stenting for the first time. Exclusion criteria were as follows: had coronary artery stenting before this hospitalization, or had severe complication during percutaneous coronary intervention (PCI) including coronary artery perforation and dissection and pericardial effusion with hemodynamic instability, or had complications during hospitalization such as rupture of ventricular septum or papillary muscle, ventricular arrhythmias required resuscitation and defibrillation, or severe congestive heart failure required invasive hemodynamic support such as intra-aortic balloon pump.

Baseline data collection

Baseline data were collected during the indexed hospitalization using a structured questionnaire administered by independent investigators. The questionnaire comprised information of demographics (age and gender), smoking status, prior medical history, risk factors, and comorbidities. Fasting venous blood was used for lipid profile, fasting plasma glucose, and liver and renal function panel assessments. Clinical presentations in terms of stable angina, unstable angina, non-STEMI (NSTEMI) or STEMI were diagnosed based on clinical manifestations, electrocardiography changes, and cardiac biomarkers by 2 independent cardiologists. The number of coronary arteries with stenosis (≥50% stenosis of coronary artery diameter) were recorded during angiography.

Clinical outcomes definition and assessment

In this study, clinical outcomes after stent placement were defined as all-cause mortality, cardiovascular death, nonfatal myocardial infarction, nonfatal ischemic stroke, UA, and coronary revascularization. Patient follow-up was at the twelfth month after discharge via telephone call and/or at outpatient department. The clinical outcomes were adjudicated by 2 independent cardiologists who did not participate in current study.

Statistical analysis

Continuous variables were expressed as mean±standard deviation (SD) or median (interquartile ranges) and categorical variables were expressed as number and frequency of cases. Between-group differences were evaluated by the independent Student t-test or the Kruskal-Wallis test for continuous variables as appropriate; or were compared by the chi-square analysis or Fisher’s exact tests for the categorical variables as appropriate. Cox proportional hazards regression analysis was used to evaluate the potential risk factors for prediction of clinical outcomes prediction. The hazard ratio (HR) and associated 95% confidence interval (CI) represents the risk associated with each 1-SD change of continuous variables or the presence of categorical variables for clinical outcomes. Statistical analysis was conducted in SPSS 23.0 (IBM, USA). All P values were 2-sided, and statistical significance was defined as P<0.05.
1107 patients with age ≤50 years were underwent PCI

1052 patients

972 included into final analysis

64 patients had outcomes and 908 patients did not have outcomes

55 did not want to participate

16 had prior coronary artery stenting, 12 had complications during PCI, 10 required invasive hemodynamic support during hospitalization, and 42 was loss of follow-up

Figure 1. Research schematic.

Results

Baseline characteristics

A total of 1107 patients with age ≤50 years who received PCI in our hospital were enrolled. Among these patients, 55 patients did not want to participate in the study, 16 patients had prior coronary artery stenting, 12 patients had complications during PCI, 10 patients required invasive hemodynamic support during hospitalization, and 42 patients was loss to follow-up (Figure 1). The remaining 972 patients were included in the final analysis, and no significant differences in the baseline characteristics were observed between the 972 patients and the excluded patients.

As presented in Table 1, the median age was 46 years old and male patients accounted for 90.2% of the included participants. The prevalence of patients who were current smokers, had hypertension, diabetes mellitus, dyslipidemia, and positive family history of CHD were 18.9%, 34.3%, 14.5%, 4.4%, and 44.2%, respectively. Before hospitalization, only 16.9%, 8.1%, 13.7%, and 10.9% of patients were treated with anti-hypertensive, anti-diabetic, anti-platelet medications, and statins, respectively.

Most of the patients underwent coronary stenting due to stable angina (48.8%) and UA (48.1%). Most of patients had cardiac function of New York Heart Association (NYHA) class I and II at baseline. Nearly 30.0%, 24.8%, 39.3%, and 5.9% of patients had single, double, triple, and left main plus triple vessel stenosis, respectively. The median number of stent implantation was 1.

Incidence of clinical outcomes after 1 years’ follow-up

zAfter the 1-year follow-up, 64 patients (6.6%) experienced clinical outcomes; the most common event was UA (n=56) and a minority of patients had nonfatal myocardial infarction (n=2), nonfatal ischemic stroke (n=4), and coronary revascularization (n=2).

Comparisons between patients with and without clinical outcomes

Baseline characteristics between patients with and without clinical outcomes were compared. As presented in Table 2, compared to patients without clinical outcomes, those with outcomes were more likely to be male, have higher systolic blood pressure, more likely to have hypertension and diabetes mellitus, and more likely to present as unstable angina.

Risk factors associated with CHD severity

The severity of CHD was divided into 3 categories with respect to the number of arteries with stenosis, the cardiac function, and the CHD classification. As presented in Table 3, male gender, hypertension, and diabetes mellitus were significantly associated with an increased number of coronary arteries with stenosis. Regarding the cardiac function, no significant risk factors were observed. However, within the category of CHD classification, increased baseline low density lipoprotein cholesterol (LDL-C) level was significantly associated with non-STEMI and STEMI.

Predictors of clinical outcomes

Cox proportional hazards regression analysis was used to evaluate potential predictors of clinical outcomes. As presented in Table 4, in the univariate regression analysis, age, male gender, smoking, serum LDL-C level, presence of hypertension and diabetes mellitus, more vessels with stenosis, and patient presenting as having acute coronary syndrome were all independently associated with incident clinical outcomes. With multivariate regression analysis, only age (HR: 1.12 and 95% CI: 1.07–1.26), smoking (HR: 1.15 and 95% CI: 1.06–1.23), presence of hypertension (HR: 1.19 and 95% CI: 1.13–1.31) and diabetes mellitus (HR: 1.16 and 95% CI: 1.09–1.28), more vessels with stenosis (HR: 1.27 and 95% CI: 1.20–1.31) and diabetes mellitus, and more likely to present as unstable angina remained independently associated with clinical outcomes.

Discussion

In the current prospective study, we found that most of young Chinese CHD patients undergoing PCI did so because of stable angina and unstable angina. Notably, approximately 45% of these patients had triple vessel stenosis and triple vessel plus left main stenosis. Nearly 6.6% of these patients 1 year after stent implantation had ischemic events in terms of unstable
Table 1. Baseline characteristics (n=972).

| Variables                                      | Value               |
|------------------------------------------------|---------------------|
| Age, years                                     | 46 (43–49)          |
| Male, n (%)                                    | 877 (90.2%)         |
| Current smoker, n (%)                          | 184 (18.9%)         |
| Systolic blood pressure, mmHg                  | 126.2±16.6          |
| Diastolic blood pressure, mmHg                 | 77.7±11.7           |
| Heart rate, beats per minute                   | 75.7±11.2           |
| Alanine aminotransferase, U/L                  | 27.9±14.8           |
| Albumin, g/L                                   | 39.0±3.1            |
| Total cholesterol, mmol/L                      | 4.74±1.13           |
| Triglyceride, mmol/L                           | 1.51 (1.06-2.19)    |
| High density lipoprotein-cholesterol, mmol/L   | 0.93±0.18           |
| Glycated hemoglobin A1c,%                     | 5.9±0.8             |
| eGFR, 1.73 m²/mL/min                           | 95.0±10.9           |
| Hypertension, n (%)                            | 333 (34.3%)         |
| Diabetes mellitus, n (%)                       | 141 (14.5%)         |
| Dyslipidemia, n (%)                            | 43 (4.4%)           |
| Family history of cardiovascular disease, n (%)| 430 (44.2%)         |
| CAD classification                             |                     |
| Stable angina, n (%)                           | 474 (48.8%)         |
| Unstable angina, n (%)                         | 468 (48.1%)         |
| Non-ST elevation myocardial infarction, n (%)  | 11 (1.1%)           |
| Left ventricular ejection fraction, %          | 57 (5.9%)           |
| Cardiac function (NYHA)                       |                     |
| Class I, n (%)                                 | 671 (69.1%)         |
| Class II, n (%)                                | 250 (25.7%)         |
| Class III, n (%)                               | 44 (4.5%)           |
| Class IV, n (%)                                | 7 (0.7%)            |
| Number of coronary arteries with stenosis      |                     |
| Single, n (%)                                  | 292 (30.0%)         |
| Double, n (%)                                  | 241 (24.8%)         |
| Triple, n (%)                                  | 382 (39.3%)         |
| Left main plus triple, n (%)                   | 57 (5.9%)           |
| Number of stents implantation*                 | 1 (0–2)             |
| Medications                                    |                     |
| Anti-hypertensive, n (%)                       | 164 (16.9%)         |
| Anti-diabetic, n (%)                           | 79 (8.1%)           |
| Anti-platelet, n (%)                           | 133 (13.7%)         |
| Statins, n (%)                                 | 106 (10.9%)         |

* Presented as median and interquartile range; NYHA=New York Heart Association; eGFR=estimated glomerular filtration rate
Table 2. Comparison between patients with and without clinical outcomes.

| Variables                                      | With outcomes (n=64) | Without outcomes (n=908) |
|------------------------------------------------|----------------------|--------------------------|
| **Age**, years                                 | 45 (42–48)           | 46 (43–49)               |
| Male, n (%)                                    | 60 (93.4%)           | 817 (90.0%)              |
| Current Smoker, n (%)                          | 12 (19.3%)           | 172 (18.9%)              |
| **Systolic blood pressure, mmHg**              | 129.4±17.5*          | 123.6±16.1               |
| Heart rate, beats per minute                   | 78.4±11.6            | 73.3±10.6                |
| **Albumin, g/L**                               | 55.9±7.3             | 57.9±8.6                 |
| **Total cholesterol, mmol/L**                  | 4.88±1.15            | 4.70±1.06                |
| Triglyceride, mmol/L                           | 1.56 (1.07–2.15)     | 1.47 (1.02–2.11)         |
| High density lipoprotein-cholesterol, mmol/L   | 0.92±0.17            | 0.93±0.17                |
| Low density lipoprotein-cholesterol, mmol/L    | 2.64±1.09            | 2.47±1.01                |
| Glycated hemoglobin A1c, %                     | 5.9±0.8              | 5.9±0.8                  |
| **eGFR, 1.73 m²/mL/min**                       | 94.5±10.7            | 95.3±11.2                |
| Hypertension, n (%)                            | 25 (38.3%)*          | 308 (33.9%)              |
| Diabetes mellitus, n (%)                       | 11 (16.7%)*          | 130 (14.3%)              |
| Dyslipidemia, n (%)                            | 3 (4.8%)             | 40 (4.4%)                |
| Family history of cardiovascular disease, n (%)| 29 (45.7%)           | 401 (44.2%)              |
| **Cardiac function (NYHA)**                    |                      |                          |
| **Stable angina, n (%)**                       | 30 (47.3%)           | 444 (48.9%)*             |
| **Unstable angina, n (%)**                     | 32 (49.5%)*          | 436 (48.0%)              |
| Non-ST elevation myocardial infarction, n (%)  | 1 (1.6%)             | 10 (1.1%)                |
| ST-elevation myocardial infarction, n (%)      | 1 (1.6%)             | 18 (2.0%)                |
| **Number of coronary arteries with stenosis**  |                      |                          |
| Single, n (%)                                  | 19 (29.5%)           | 273 (30.1%)              |
| Double, n (%)                                  | 16 (25.3%)           | 225 (24.8%)              |
| Triple, n (%)                                  | 25 (39.7%)           | 357 (39.3%)              |
| Left main plus triple, n (%)                   | 4 (6.4%)             | 53 (5.8%)                |
| Left ventricular ejection fraction, %          | 55.9±7.1             | 55.9±7.1                 |
| **Number of stents implantation#**             | 1 (0–2)              | 1 (0–2)                  |
| **Medications**                                |                      |                          |
| Anti-hypertensive, n (%)                       | 10 (16.2%)           | 254 (11.0%)              |
| Anti-diabetic, n (%)                           | 5 (7.8%)             | 74 (8.1%)                |
| Anti-platelet, n (%)                           | 8 (12.8%)            | 125 (13.8%)              |
| Statins, n (%)                                 | 7 (10.2%)*           | 99 (10.9%)               |

* Presented as median and interquartile range; *P<0.05 versus without outcomes group. CHD — coronary heart disease; NYHA — New York Heart Association; eGFR — estimated glomerular filtration rate.
Cox proportional hazards regression analysis indicated that age, smoking, presence of hypertension and diabetes mellitus, the number of vessels with stenosis, and acute coronary syndrome presentation during admission were independently associated with ischemic events.

The prevalence and incidence of hypertension, diabetes mellitus, and dyslipidemia has dramatically increased in the last 3 decades in China due to economic development [12–16]. These comorbidities together contribute to the initiation and progression of CHD. The prevalence and incidence of CHD among young adults has been reported to be similar to the ageing population in China [17,18], which is a big challenge to the health and economic system due to health-related productivity loss [19].

Coronary artery stenting is an effective and efficient approach for restoring myocardial reperfusion and improving cardiac function. However, a large proportion of patients with coronary artery stenting still experience ischemic events over time [20,21], and the underlying mechanisms might be due to poor risk factor management and/or poor adherence to medications [22].

In this prospective study, we firstly evaluate the clinical characteristics of young CHD patients with coronary artery stenting. We found that premature CHD was more common in male

### Table 3. Comparisons of risk factors of CHD severity.

| Number of artery stenosis | Single (n=292) | Double (n=241) | Triple/Left main+triple (n=439) | P value |
|---------------------------|---------------|---------------|---------------------------------|---------|
| **Age**                   | 46 (42–49)    | 46 (43–49)    | 46 (43–49)                      | 0.691   |
| **LDL-C**                 | 2.49±1.04     | 2.51±1.07     | 2.52±1.06                      | 0.860   |
| **Male**                  | 257 (88.0)    | 224 (92.9)    | 414 (94.3)                      | 0.007   |
| **Current smoker**        | 58 (20.1)     | 49 (20.5)     | 83 (19.0)                       | 0.878   |
| **Hypertension**          | 78 (26.8)     | 85 (35.4)     | 185 (42.2)                      | <0.001  |
| **Diabetes mellitus**     | 30 (10.3)     | 37 (15.4)     | 87 (19.9)                       | 0.002   |

| Cardiac function (NYHA)  | Class I (n=671) | Class II (n=250) | Class III–IV (n=51) | P value |
|---------------------------|-----------------|------------------|---------------------|---------|
| **Age**                   | 46 (43–49)      | 46 (43–49)       | 46 (42–48)          | 0.936   |
| **LDL-C**                 | 2.48±1.05       | 2.50±1.03        | 2.51±1.06           | 0.546   |
| **Male**                  | 614 (91.6)      | 274 (93.6)       | 46 (90.2)           | 0.545   |
| **Current smoker**        | 123 (18.5)      | 54 (21.7)        | 13 (25.5)           | 0.320   |
| **Hypertension**          | 218 (32.6)      | 109 (43.8)       | 21 (41.2)           | 0.075   |
| **Diabetes mellitus**     | 95 (14.2)       | 48 (19.4)        | 10 (19.6)           | 0.125   |

| CHD classification        | Stable (n=474)  | Unstable (n=468) | Non–STEMI/STEMI (n=30) | P value |
|---------------------------|-----------------|------------------|------------------------|---------|
| **Age**                   | 46 (42–49)      | 46 (43–49)       | 45 (43–48)             | 0.512   |
| **LDL-C**                 | 2.45±1.06       | 2.49±1.04        | 2.53±1.09              | 0.010   |
| **Male**                  | 432 (91.1)      | 435 (92.9)       | 28 (93.3)              | 0.570   |
| **Current smoker**        | 71 (15.4)       | 112 (24.1)       | 7 (23.3)               | 0.092   |
| **Hypertension**          | 180 (38.1)      | 161 (34.5)       | 7 (23.3)               | 0.174   |
| **Diabetes mellitus**     | 73 (15.5)       | 78 (16.7)        | 3 (10.0)               | 0.579   |

* Continuous variables were presented as median and interquartile range, tested with Kruskal-Wallis Test; categorical variables are presented as n (%), tested with chi-square tests and linear-by-linear association. CHD – coronary heart disease; LDL-C – low density lipoprotein cholesterol; NYHA – New York Heart Association; STEMI – ST-segment elevation myocardial infarction.
patients which might be due to more risk factors among males versus females. In addition, estrogen might also play a protective role in the young female patients [23]. We also observed that the treatment for risk factors in the young CHD patients before admission were also low, with only 16.9%, 8.1%, 13.7%, and 10.9% of patients treated with anti-hypertensive, anti-diabetic, anti-platelet medications, and statins, respectively. These data strongly support the notion that risk factor treatment is essential to prevent CHD [24]. Interestingly and importantly, we found that the reason most of young CHD patients underwent coronary artery stenting was not due to myocardial infarction. Rather, nearly 96.8% of these patients underwent coronary artery stenting due to chest pain. We are unsure about the underlying mechanisms. However, these data indicate that in young CHD patients, cardiac stress testing might be helpful to timely identify those who are at risk for cardiovascular events [25].

We secondly evaluate the risk factors of CHD severity in order to identify potential modifiable factors. We divided the severity of CHD into 3 categories in terms of the number of arteries with stenosis, cardiac function, and CHD classification. We found that male gender, hypertension, and diabetes mellitus were all significantly associated with increased number of coronary arteries with stenosis. However, regarding the cardiac function, no significant risk factors were observed. Only increased baseline serum LDL-C level was significantly associated with non-STEMI and STEMI. Once again, these findings suggest that controlling risk factors in terms of hypertension, dyslipidemia, and diabetes mellitus could help to prevent CHD progression and reduce the severity of CHD.

We lastly evaluate the predictors of cardiovascular outcomes in the young CHD patients after coronary artery stenting. At the 1-year follow-up, among the 972 participants, 64 patients (6.6%) had clinical outcomes and the most common event was unstable angina, while a minority of patients had non-fatal myocardial infarction, nonfatal ischemic stroke, and coronary revascularization, indicating the most common ischemic events of the young CHD study patients after coronary artery stenting were due to chest pain. The underlying mechanisms might be due to anxiety after coronary artery stenting or disease progression. Future studies are warranted to evaluate the anxiety status of these young patients after coronary artery stenting. In addition, cardiac stress testing could also be helpful to identify the progression of disease.

We compared the baseline clinical characteristics between patients with and without clinical outcomes. We found that those with outcomes were more likely to be male, have higher systolic blood pressure, more likely to have hypertension and diabetes mellitus, and more likely to be presented as unstable angina. Cox proportional hazards regression analysis shows that age, smoking, presence of hypertension and diabetes mellitus, more vessels with stenosis and patient presenting with acute coronary syndrome were independently associated with

---

Table 4. Cox proportional hazards regression analysis.

| Variables                                      | Studied outcomes                      | Univariate HR (95% CI) | Multivariate HR (95% CI) |
|------------------------------------------------|---------------------------------------|------------------------|--------------------------|
| Age, years                                     |                                       | 1.25 (1.16–1.39)       | 1.12 (1.07–1.26)         |
| Male vs. Female                                |                                       | 1.18 (1.06–1.27)       | 1.05 (0.94–1.11)         |
| Smoker vs. non-smoker                          |                                       | 1.27 (1.14–1.40)       | 1.15 (1.06–1.23)         |
| LDL-C, mmol/L                                  |                                       | 1.15 (1.06–1.52)       | 1.09 (0.98–1.07)         |
| HbA1c, %                                       |                                       | 1.06 (0.97–1.12)       | NA                      |
| eGFR, 1.73 m²/mL/min                           |                                       | 1.08 (0.95–1.07)       | NA                      |
| Hypertension (presence vs. absence)            |                                       | 1.30 (1.18–1.53)       | 1.19 (1.13–1.31)         |
| Diabetes mellitus (presence vs. absence)       |                                       | 1.28 (1.17–1.50)       | 1.16 (1.09–1.28)         |
| Cardiac function (III/IV vs. I/II)             |                                       | 1.08 (0.92–1.14)       | NA                      |
| Number of artery stenosis (triple/left main plus triple vs. single/two) | | 1.39 (1.26–1.55)       | 1.27 (1.20–1.48)         |
| CHD classification (acute coronary syndrome vs. stable angina) | | 1.44 (1.29–1.64)       | 1.35 (1.21–1.55)         |

LDL-C – low density lipoprotein cholesterol; eGFR – estimated glomerular filtration rate; CHD – coronary heart disease; NA – non-applicable; HR – hazard ratio; CI – confidence interval. Acute coronary syndrome includes unstable angina, non-STEMI and STEMI.
clinical outcomes. These findings strongly indicated that controlling the modifiable risk factors including smoking, hypertension, and diabetes mellitus would be beneficial to prevent ischemic events after stenting. In addition, in male patients and patients with more vessels with stenosis and those who presented with acute coronary syndrome, close follow-up and optimization of risk factors would also be helpful.

The clinical implications of current study were as follows: 1) young CHD patients had specific clinical characteristics and physicians should better screen and recognize the age-specific characteristics; 2) independent risk factors identified in this study might be used to establish risk predictive model in the future; 3) physicians should better manage the risk factors which might help to improve outcome for young CHD patients. For example, both physicians and social media should advocate and encourage young CHD patients to stop smoking; financial incentive might also help. Regarding hypertension and diabetes mellitus, not only should there be better screening, but also there should be increased utilization of guideline-recommended medications to treat these comorbidities. In addition, young people should be encouraged to live a healthy lifestyle such as stop smoking, eat more vegetables, and do regular exercise, which might reduce systemic inflammation and retard atherosclerosis progress. Finally, multidisciplinary team and holistic approach might provide a comprehensive management of CHD in young patients. In addition, based on our study findings, future research should focus on: 1) whether targeting the age-specific risk factors could result in greater benefits in younger rather than older CHD patients; 2) multi-center clinical studies are needed to establish and validate risk predictive model for young CHD patients.

References:

1. Wirtz VJ, Kaplan WA, Kwan GF, Laing RO: Access to medications for cardiovascular diseases in low- and middle-income countries. Circulation, 2016; 133(21): 2076–85
2. Christiansen MN, Kaber I, Weeke P: Age-specific trends in incidence, mortality, and comorbidities of heart failure in Denmark, 1995 to 2012. Circulation, 2017; 135(13): 1214–23
3. Tzoulaki I, Elliott P, Kontis V, Ezzati M: Worldwide exposures to cardiovascular risk factors and associated health effects: Current knowledge and data gaps. Circulation, 2016; 133(23): 2314–33
4. Wang W, Jiang B, Sun H: Prevalence, incidence, and mortality of stroke in China: Results from a nationwide population-based survey of 480 687 Adults. Circulation, 2017; 135(8): 759–71
5. Parkash R, Wells GA, Sapp JL: Effect of aggressive blood pressure control on the recurrence of atrial fibrillation after catheter ablation: A randomized, open-label clinical trial (SMAC-AF [substrate modification with aggressive blood pressure control]). Circulation, 2017; 135(19): 1788–98
6. Arnold SV, Sputers JA, Jones PG: Predicting adverse outcomes after myocardial infarction among patients with diabetes mellitus. Circ Cardiovasc Qual Outcomes, 2016; 9(4): 372–79
7. Natarajan P, Young R, Stitziel NO: Polygenic risk score identifies subgroup with higher burden of atherosclerosis and greater relative benefit from statin therapy in the primary prevention setting. Circulation, 2017; 135(22): 2091–101
8. Li J, Li X, Wang Q: ST-segment elevation myocardial infarction in China from 2001 to 2011 (the China PEACE-Retrospective Acute Myocardial Infarction Study): A retrospective analysis of hospital data. Lancet, 2015; 385(9966): 441–51
9. Chen WW, Gao RL, Liu LS et al: China cardiovascular diseases report 2015: A summary. J Geriatr Cardiol, 2017; 14(1): 1–10
10. Li X, Murugiah K, Li J: Urban-rural comparisons in hospital admission, treatments, and outcomes for ST-segment-elevation myocardial infarc tion in China from 2001 to 2011: A retrospective analysis from the China PEACE study (patient-centered evaluative assessment of cardiac events). Circ Cardiovasc Qual Outcomes, 2017; 10(11): pii: e003905
11. Wang X, Gao M, Zhou S: Trend in young coronary artery disease in China from 2010 to 2014: a retrospective study of young patients ≤45. BMC Cardiovasc Disord, 2017; 17(1): 18
12. Cai A, Zhong Q, Liu C: Associations of systolic and diastolic blood pressure night-to-day ratios with atherosclerotic cardiovascular diseases. Hypertens Res, 2016; 39(12): 874–78

There were several limitations to our study. First of all, this was a single center study and the findings from this study should be further corroborated in other areas and medical centers of China. Second, we did not obtain information about the medication usage during follow-up which did not allow us to evaluate the adherence to treatment of these young CHD patients. Moreover, we also did not evaluate the control rate of risk factors during follow-up. Third, most of the ischemic events were unstable angina. As we discussed, some of these symptoms might be due to anxiety or other diseases such as gastric esophagus regurgitation disorder. Long-term follow-up for clinical events such as myocardial infarction, plus cardiac stress testing could be helpful to evaluate the outcomes of these young CHD patients.

Conclusions

Our current study indicated that most of the young CHD patients underwent coronary artery stenting due to angina, and poor management of risk factors contributed to the development of premature coronary artery stenosis. Physicians should better screen and recognize age-specific characteristics. In addition, better management of these risk factors would be beneficial for improving clinical outcomes for young CHD populations.

Acknowledgment

We thank Chen Zhang, PhD, for assisting us in performing statistical analysis of our paper.

Conflict of interests

None.
13. Luo B, Zhang J, Hu Z: Diabetes-related behaviors among elderly people with pre-diabetes in rural communities of Hunan, China: A cross-sectional study. BMJ Open, 2018; 8(1) e015747
14. Zhang FL, Guo ZN, Xing YQ: Hypertension prevalence, awareness, treatment, and control in northeast China: A population-based cross-sectional survey. J Hum Hypertens, 2017; 32(1): 54–65
15. Yan L, Xu MT, Yuan L: Prevalence of dyslipidemia and its control in type 2 diabetes: A multicenter study in endocrinology clinics of China. J Clin Lipidol, 2016; 10(1): 150–60
16. Pan L, Yang Z, Wu Y: The prevalence, awareness, treatment and control of dyslipidemia among adults in China. Atherosclerosis, 2016; 248: 2–9
17. Gao N, Yuan Z, Tang X: Prevalence of CHD-related metabolic comorbidity of diabetes mellitus in Northern Chinese adults: the REACTION study. J Diabetes Complications, 2016; 30(2): 199–205
18. Zhang XH, Lu ZL, Liu L: Coronary heart disease in China. Heart, 2008; 94(9): 1126–31
19. Moran A, Gu D, Zhao D: Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-China. Circ Cardiovasc Qual Outcomes, 2010; 3(3): 243–52
20. Thel MC, Califf RM, Tardiff BE: Timing of and risk factors for myocardial ischemic events after percutaneous coronary intervention (IMPACT-II). Integrilin to minimize platelet aggregation and coronary thrombosis. Am J Cardiol, 2000; 85(4): 427–34
21. Cai A, Li G, Chen J: Glycated hemoglobin level is significantly associated with the severity of coronary artery disease in non-diabetic adults. Lipids Health Dis, 2014; 13: 181
22. Cooney MT, Kotseva K, Dudina A: Determinants of risk factor control in subjects with coronary heart disease: A report from the EUROASPIRE III investigators. Eur J Prev Cardiol, 2013; 20(4): 686–91
23. Yao MF, He J, Sun X: Gender differences in risks of coronary heart disease and stroke in patients with type 2 diabetes mellitus and their association with metabolic syndrome in China. Int J Endocrinol, 2016; 2016: 8483405
24. Zhong Z, Liu J, Zhang Q et al: Relationship between preoperative low-density lipoprotein cholesterol and periprocedural myocardial injury in patients following elective percutaneous coronary intervention in southern China. Med Sci Monit, 2018; 24: 4154–61
25. Shah N, Soon K, Wong C, Kelly AM: Screening for asymptomatic coronary heart disease in the young ‘at risk’ population: Who and how. Int J Cardiol Heart Vasc, 2015; 6: 60–65

Indexed in: [Current Contents/Clinical Medicine] [SCI Expanded] [ISI Alerting System] [ISI Journals Master List] [Index Medicus/MEDLINE] [EMBASE/Excerpta Medica] [Chemical Abstracts/CAS]

This work is licensed under Creative Common Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)